Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6.

View in: PubMed

subject areas

Alleles
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carcinoma, Renal Cell
Disease Progression
Humans
Hypoxia
Interferon-alpha
Kidney Neoplasms
Neoplasm Metastasis
Prognosis
Proportional Hazards Models
Time Factors
Tumor Suppressor Proteins
Ubiquitin-Protein Ligases
Vascular Endothelial Growth Factor A
Von Hippel-Lindau Tumor Suppressor Protein

authors with profiles

Richard Schilsky